Fig. 2.

TME-IgG promotes tumor growth by decreasing the proportions of both CD4⁺ and CD8⁺ T cells. a Establishment of mouse models used in (b–h). b On the 6th day after subcutaneous (s.c.) injection of B16 cells, 5 μg or 20 μg TME-IgG dissolved in 100 μl PBS (n = 5 per group), IVIG (n = 6 (5 μg), and n = 5 (20 μg)), or 100 μl PBS (n = 6 per group) was injected subcutaneously into the peritumoral area, and the tumor volume of each group was measured. Images of the tumors were taken (c), and tumor weights (d) were measured on day 14 in mice, as in (b). e Proportions of T and B lymphocytes in the draining lymph nodes (DLNs) of each group (TME-IgG, n = 7 (four samples from the 20-μg group and three samples from the 5-μg group); IVIG, n = 7 (four samples from the 20-μg group and three samples from the 5-μg group); and PBS, n = 5). Tumor growth curves of nude mice (TME-IgG, n = 8; IVIG and PBS, n = 6) or wild-type C57BL/6 mice (n = 6 for each group) treated with 20 μg TME-IgG or IVIG dissolved in PBS or the same volume of PBS (control) are shown in (f). Tumor volume (g) and weight (h) were measured on the 17th day after B16 implantation. Each symbol represents an individual tumor sample; small horizontal lines indicate the mean ( ± s.e.m. in b, d, and e; ± s.d. in f, g, and h). ns, not significant (P ≥ 0.05); ^*P ≤ 0.05; and ^**P ≤ 0.01 (one-way analysis of variance (ANOVA) followed by Tukey’s multiple-comparisons test (b, d, e–h)). Data are from one experiment that was representative of four (b–e) independent experiments with similar results. Also see Supplementary Fig. S2.